|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2006-6-9
|
|
pubmed:abstractText |
Lamivudine treatment is associated with frequent development of resistant hepatitis B virus (HBV) and loss of treatment benefit. In preclinical and phase II studies, entecavir demonstrated potent antiviral activity against lamivudine-resistant HBV.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0016-5085
|
|
pubmed:author |
pubmed-author:AI463026 BEHoLD Study Group,
pubmed-author:Boron-KaczmarskaAnnaA,
pubmed-author:CianciaraJanuszJ,
pubmed-author:ColonnoRichardR,
pubmed-author:CrossAnneA,
pubmed-author:DeniskyGailG,
pubmed-author:GoodmanZacharyZ,
pubmed-author:HindesRobertR,
pubmed-author:KreterBruceB,
pubmed-author:LiawYun-FanYF,
pubmed-author:MartinPaulP,
pubmed-author:ShermanMorrisM,
pubmed-author:SilvaMarceloM,
pubmed-author:SollanoJoseJ,
pubmed-author:YurdaydinCihanC
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
130
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2039-49
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:16762627-Adolescent,
pubmed-meshheading:16762627-Adult,
pubmed-meshheading:16762627-Aged,
pubmed-meshheading:16762627-Confidence Intervals,
pubmed-meshheading:16762627-Cross-Over Studies,
pubmed-meshheading:16762627-Dose-Response Relationship, Drug,
pubmed-meshheading:16762627-Double-Blind Method,
pubmed-meshheading:16762627-Drug Administration Schedule,
pubmed-meshheading:16762627-Drug Resistance, Viral,
pubmed-meshheading:16762627-Female,
pubmed-meshheading:16762627-Follow-Up Studies,
pubmed-meshheading:16762627-Guanine,
pubmed-meshheading:16762627-Hepatitis B, Chronic,
pubmed-meshheading:16762627-Hepatitis B e Antigens,
pubmed-meshheading:16762627-Hepatitis B virus,
pubmed-meshheading:16762627-Humans,
pubmed-meshheading:16762627-Lamivudine,
pubmed-meshheading:16762627-Liver Function Tests,
pubmed-meshheading:16762627-Male,
pubmed-meshheading:16762627-Middle Aged,
pubmed-meshheading:16762627-Probability,
pubmed-meshheading:16762627-Reference Values,
pubmed-meshheading:16762627-Risk Assessment,
pubmed-meshheading:16762627-Severity of Illness Index,
pubmed-meshheading:16762627-Treatment Outcome,
pubmed-meshheading:16762627-Viral Load
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B.
|
|
pubmed:affiliation |
Department of Medicine, Toronto General Hospital, Toronto, Ontario, Canada. Dr.Morris.sherman@uhn.on.ca
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Randomized Controlled Trial,
Clinical Trial, Phase III
|
